Daily Cardiology Research Analysis
Analyzed 93 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out today: a prespecified subgroup of the MASTER DAPT randomized trial showed that abbreviated dual antiplatelet therapy reduced bleeding without increasing ischemic events even after bifurcation PCI in high bleeding risk patients. A UK Biobank prospective cohort linked systemic inflammatory indices (higher SIRI, lower LMR) to incident aortic stenosis and mitral regurgitation. A proof-of-concept randomized trial found no incremental reduction in carotid plaque inflammation (18F-FDG PET/CT) when adding low-dose rivaroxaban to aspirin.
Research Themes
- Optimizing antithrombotic therapy duration after PCI in high bleeding risk settings
- Systemic inflammation as a driver of non-rheumatic valvular heart disease
- Imaging biomarkers to test anti-inflammatory effects of cardiovascular therapies
Selected Articles
1. Abbreviated Dual Antiplatelet Therapy in Patients With High Bleeding Risk Undergoing PCI of Bifurcation Lesions: A Prespecified Substudy of the MASTER DAPT Trial.
In this prespecified subgroup of MASTER DAPT, among high bleeding risk patients who underwent bifurcation PCI, abbreviated DAPT reduced bleeding without increasing ischemic or net adverse events versus standard DAPT at 335 days. Similar safety and efficacy were observed irrespective of bifurcation PCI status.
Impact: Provides randomized evidence supporting abbreviated DAPT even in complex bifurcation PCI among high bleeding risk patients, directly informing antithrombotic strategies.
Clinical Implications: For high bleeding risk patients undergoing bifurcation PCI, an abbreviated DAPT regimen can be considered to lower bleeding without compromising ischemic protection, aligning with individualized therapy.
Key Findings
- Among 976 patients with bifurcation PCI, abbreviated DAPT showed no increase in net adverse clinical events versus standard DAPT (HR 0.98, 95% CI 0.73-1.17).
- Major adverse cardiac and cerebral events were similar between abbreviated and standard DAPT after bifurcation PCI (HR 0.92, 95% CI 0.63-1.54).
- Abbreviated DAPT reduced BARC 2–5 bleeding without excess ischemic events in high bleeding risk patients irrespective of bifurcation PCI status.
Methodological Strengths
- Randomized comparison within a prespecified subgroup of a multicenter RCT
- Standardized bleeding endpoint (BARC) and clinically relevant composite outcomes at 335 days
Limitations
- Open-label design may introduce performance bias
- Subgroup analysis may be underpowered for some ischemic endpoints
Future Directions: Confirm efficacy and safety across bifurcation strategies (one- vs two-stent), stent platforms, and longer follow-up; integrate bleeding and ischemic risk models for individualized DAPT duration.
BACKGROUND: Coronary stenting of bifurcation lesions has been associated with an increased risk of thrombotic events. However, the optimal duration of dual antiplatelet therapy (DAPT) after treatment of bifurcations, particularly among patients with high bleeding risk, is unknown. We aimed to evaluate the safety and efficacy of abbreviated DAPT in patients with high bleeding risk undergoing percutaneous coronary intervention (PCI) of bifurcation lesions. METHODS: The MASTER DAPT trial (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen) randomized patients with high bleeding risk who were free from ischemic or bleeding events after 1 month of PCI to discontinue DAPT (abbreviated regimen) or continue DAPT for a minimum of 2 additional months (standard regimen). Coprimary outcomes were net adverse clinical outcomes events, major adverse cardiac and cerebral events, and BARC (Bleeding Academic Research Consortium) type 2, 3, or 5 bleeding at 335 days after randomization. This prespecified substudy evaluates the outcomes of abbreviated versus standard DAPT according to treatment of bifurcation lesions. RESULTS: Of the 4579 patients randomized, 976 (21.2%) underwent bifurcation PCI. Net adverse clinical event and major adverse cardiac and cerebral events did not differ between abbreviated and standard DAPT in both patients with (hazard ratio [HR], 0.98 [95% CI, 0.73-1.17] and HR, 0.92 [95% CI, 0.63-1.54], respectively) and without bifurcation PCI (HR, 1.14 [95% CI, 0.67-1.93] and HR, 0.96 [95% CI, 0.74-1.25]; CONCLUSIONS: Among patients with high bleeding risk with or without bifurcation PCI, abbreviated DAPT was associated with lower bleeding risk without an excess of ischemic or net adverse events compared with standard DAPT. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03023020.
2. Association of systemic inflammatory indicators with incident valvular heart disease: a prospective analysis of the UK Biobank.
In over 250,000 UK Biobank participants free of baseline CVD and autoimmune disease, higher SIRI and lower LMR independently predicted incident aortic stenosis, mitral regurgitation, and valve-related events over 13.2 years. No clear association was seen for aortic regurgitation after full adjustment.
Impact: Links simple, routinely available inflammatory indices to incident valvular disease at population scale, highlighting inflammation as a modifiable pathway and enabling risk enrichment strategies.
Clinical Implications: Inflammation-based indices (e.g., SIRI, LMR) could complement clinical and imaging data to identify individuals at higher risk of AS or MR for closer surveillance and preventive strategies.
Key Findings
- Higher SIRI was associated with increased risk of incident aortic stenosis (HR per 1-SD 1.07; 95% CI 1.03–1.11) and mitral regurgitation (HR 1.10; 95% CI 1.05–1.14).
- Higher LMR was inversely associated with incident AS (HR 0.91; 95% CI 0.86–0.96), MR (HR 0.93; 95% CI 0.89–0.98), and valve-related events (HR 0.88; 95% CI 0.82–0.94).
- No clear association with aortic regurgitation was detected after full adjustment; findings were consistent across sensitivity and dose-response analyses.
Methodological Strengths
- Very large prospective cohort with long follow-up (median 13.22 years)
- Robust multivariable Cox models with sensitivity, subgroup, and spline analyses
Limitations
- Observational design subject to residual confounding and misclassification
- Single baseline measurement of inflammatory indices may not capture temporal variability
Future Directions: Integrate inflammatory indices with imaging biomarkers (e.g., CT calcium, echocardiography) to build predictive models and test anti-inflammatory interventions for preventing AS/MR.
BACKGROUND: Systemic inflammation has been implicated in valvular degeneration, but prospective evidence across major non-rheumatic valvular phenotypes remains limited. We investigated the associations of circulating inflammatory indicators with incident valvular heart disease in the UK Biobank. METHODS: This prospective cohort study included 250,532 participants free of cardiovascular disease, valvular heart disease, and autoimmune disease at baseline. Baseline systemic inflammation response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-platelet ratio (NPR), lymphocyte-to-monocyte ratio (LMR), and C-reactive protein were assessed. Multivariable Cox proportional hazards models were used to examine associations with clinically diagnosed incident aortic stenosis (AS), mitral regurgitation (MR), aortic regurgitation (AR), and valve-related events. Restricted cubic spline analyses, subgroup analyses, and sensitivity analyses were performed. RESULTS: Over a median follow-up of 13.22 years, incident AS occurred in 1,904 participants, incident MR in 2,140, and incident AR in 757; 1,369 valve-related events were also recorded. Higher SIRI was associated with increased risks of AS (hazard ratio [HR] per 1-standard deviation [SD], 1.07; 95% CI, 1.03-1.11), MR (1.10; 1.05-1.14), and valve-related events (1.08; 1.03-1.13). Higher LMR was associated with lower risks of AS (0.91; 0.86-0.96), MR (0.93; 0.89-0.98), and valve-related events (0.88; 0.82-0.94). NPR was positively associated with MR and valve-related events, whereas no indicators showed a clear association with AR after full adjustment. These patterns were broadly consistent across dose-response, subgroup, and sensitivity analyses. CONCLUSIONS: Systemic inflammatory indices, particularly SIRI and LMR, were independently associated with incident AS, MR, and valve-related events, whereas no clear association was detected for AR. These findings support a phenotype-specific relationship between systemic inflammation and non-rheumatic valvular heart disease. This large prospective study using data from the UK Biobank investigated the associations between systemic inflammatory indicators and the risk of clinically diagnosed incident non-rheumatic valvular heart disease. Key finding 1: Higher systemic inflammation, particularly higher systemic inflammation response index (SIRI) and lower lymphocyte-to-monocyte ratio (LMR), was associated with a higher risk of aortic stenosis, mitral regurgitation, and valve-related events, whereas no clear association was observed for aortic regurgitation.Key finding 2: These findings suggest that systemic inflammation may be related to the development of selected valvular heart disease phenotypes. Because these indicators are derived from routine blood tests, they may help inform future research on risk assessment when combined with conventional clinical and imaging data.
3. Effect of Low-Dose Rivaroxaban Plus Aspirin on 18F-FDG PET/CT-Detectable Carotid Plaque Inflammation: A Randomised Trial.
In patients with asymptomatic carotid stenosis and elevated FDG uptake, low-dose rivaroxaban added to aspirin did not reduce carotid plaque inflammation on FDG PET/CT versus aspirin alone at 12 months. Minor bleeding was more frequent with combination therapy, with no major bleeding or deaths.
Impact: Provides randomized, imaging-based evidence refuting an anti-inflammatory effect of vascular-dose rivaroxaban on carotid plaque over 12 months, refining mechanistic expectations from dual-pathway inhibition.
Clinical Implications: For patients with carotid atherosclerosis, adding low-dose rivaroxaban to aspirin should not be expected to reduce plaque inflammation; treatment decisions should prioritize clinical event reduction and bleeding risk.
Key Findings
- No difference in percent change of most-diseased-segment carotid TBR at 12 months between aspirin+rivaroxaban (-7.25%) and aspirin alone (-7.36%); adjusted difference -1.50 percentage points (P=0.529).
- Secondary imaging endpoints (whole-vessel carotid and aortic TBR) were concordant with the primary outcome.
- Minor bleeding occurred in 8.7% with combination therapy vs 2.2% with aspirin; no major bleeding or deaths.
Methodological Strengths
- Randomized design with blinded endpoint assessment using standardized FDG PET/CT metrics
- Targeted inclusion of patients with elevated baseline carotid FDG uptake to enrich for inflammatory activity
Limitations
- Single-centre, proof-of-concept trial with modest sample size limits power
- Open-label treatment allocation and reliance on surrogate imaging endpoints
Future Directions: Evaluate alternative anti-inflammatory or antithrombotic regimens, different imaging modalities or tracers, and longer durations; explore responders based on baseline inflammatory burden.
AIMS: Aspirin plus low-dose rivaroxaban reduces cardiovascular events in stable atherosclerosis; its effect on arterial inflammation in humans remains unclear. We tested whether adding low-dose rivaroxaban to aspirin reduces 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT)-detectable carotid plaque inflammation. METHODS AND RESULTS: In this single-centre, randomised, open-label, proof-of-concept trial with blinded endpoint assessment, adults with asymptomatic carotid stenosis (20%-80%) and elevated carotid FDG uptake (target-to-background ratio [TBR] ≥ 1.6) were assigned 1:1 to aspirin (100 mg/day) plus rivaroxaban (2.5 mg twice daily) or aspirin alone. The primary endpoint was percent change in the most diseased segment (MDS) TBR of the index carotid artery at 12 months. Secondary endpoints included whole-vessel carotid TBR, aortic TBR, lipid and high-sensitivity C-reactive protein (hsCRP) changes. From September 2021 to December 2023, 92 patients were randomised (mean age 69.4 years; 88% men), and 81 (88%) completed paired imaging. Mean percent changes in MDS TBR were -7.25% (95% confidence interval [CI], -11.03 to -3.48) with combination therapy and -7.36% (95% CI, -11.06 to -3.67) with aspirin alone (adjusted between-group difference, -1.50 percentage points, 95% CI, -6.20 to 3.21; P = 0.529). Secondary imaging endpoints were concordant. Laboratory parameters were similar, except for a nominal hsCRP difference without multiplicity adjustment. Minor bleeding occurred in four (8.7%) and one (2.2%) patients, respectively; no major bleeding or deaths occurred. CONCLUSIONS: In patients with carotid atherosclerosis, adding low-dose rivaroxaban to aspirin did not produce a detectable incremental reduction in 18F-FDG PET/CT-assessed carotid plaque inflammation compared with aspirin alone over 12 months.